Michelle So1, Colin O'Rourke1, Henry T Bahnson1, Carla J Greenbaum1, Cate Speake2. 1. Diabetes Clinical Research Program, Benaroya Research Institute at Virginia Mason, Seattle, WA. 2. Diabetes Clinical Research Program, Benaroya Research Institute at Virginia Mason, Seattle, WA cspeake@benaroyaresearch.org.
Abstract
OBJECTIVE: Most individuals with two or more islet autoantibodies progress to clinical type 1 diabetes. However, in some individuals, autoantibodies are subsequently lost. Here, our objectives were to determine the frequency of autoantibody loss (reversion) in multiple-autoantibody-positive individuals and to determine the association between reversion and progression to clinical disease. RESEARCH DESIGN AND METHODS: We analyzed multiple-autoantibody-positive individuals participating in TrialNet's Pathway to Prevention Study for reversion and determined the effect of reversion on progression to clinical disease using a Cox regression analysis. RESULTS: Of 3,284 multiple-autoantibody-positive subjects, reversion occurred in 134 (4.1%) and was associated with reduced incidence of clinical disease. Reversion occurred more frequently with older age, lower autoantibody titers, and fewer positive autoantibodies. CONCLUSIONS: Although reversion of multiple-autoantibody positivity is rare, when it occurs, the risk of progressing to clinical disease is reduced. This suggests unknown mechanisms promoting immune remission in some individuals.
OBJECTIVE: Most individuals with two or more islet autoantibodies progress to clinical type 1 diabetes. However, in some individuals, autoantibodies are subsequently lost. Here, our objectives were to determine the frequency of autoantibody loss (reversion) in multiple-autoantibody-positive individuals and to determine the association between reversion and progression to clinical disease. RESEARCH DESIGN AND METHODS: We analyzed multiple-autoantibody-positive individuals participating in TrialNet's Pathway to Prevention Study for reversion and determined the effect of reversion on progression to clinical disease using a Cox regression analysis. RESULTS: Of 3,284 multiple-autoantibody-positive subjects, reversion occurred in 134 (4.1%) and was associated with reduced incidence of clinical disease. Reversion occurred more frequently with older age, lower autoantibody titers, and fewer positive autoantibodies. CONCLUSIONS: Although reversion of multiple-autoantibody positivity is rare, when it occurs, the risk of progressing to clinical disease is reduced. This suggests unknown mechanisms promoting immune remission in some individuals.
Authors: J Yu; L Yu; T L Bugawan; H A Erlich; K Barriga; M Hoffman; M Rewers; G S Eisenbarth Journal: J Clin Endocrinol Metab Date: 2000-07 Impact factor: 5.958
Authors: Jennifer M Barker; Katherine J Barriga; Liping Yu; Dongmei Miao; Henry A Erlich; Jill M Norris; George S Eisenbarth; Marian Rewers Journal: J Clin Endocrinol Metab Date: 2004-08 Impact factor: 5.958
Authors: T Kimpimäki; P Kulmala; K Savola; A Kupila; S Korhonen; T Simell; J Ilonen; O Simell; M Knip Journal: J Clin Endocrinol Metab Date: 2002-10 Impact factor: 5.958
Authors: Liping Yu; David C Boulware; Craig A Beam; John C Hutton; Janet M Wenzlau; Carla J Greenbaum; Polly J Bingley; Jeffrey P Krischer; Jay M Sosenko; Jay S Skyler; George S Eisenbarth; Jeffrey L Mahon Journal: Diabetes Care Date: 2012-03-23 Impact factor: 19.112
Authors: Richard A Insel; Jessica L Dunne; Mark A Atkinson; Jane L Chiang; Dana Dabelea; Peter A Gottlieb; Carla J Greenbaum; Kevan C Herold; Jeffrey P Krischer; Åke Lernmark; Robert E Ratner; Marian J Rewers; Desmond A Schatz; Jay S Skyler; Jay M Sosenko; Anette-G Ziegler Journal: Diabetes Care Date: 2015-10 Impact factor: 19.112
Authors: Kendra Vehik; Kristian F Lynch; Desmond A Schatz; Beena Akolkar; William Hagopian; Marian Rewers; Jin-Xiong She; Olli Simell; Jorma Toppari; Anette-G Ziegler; Åke Lernmark; Ezio Bonifacio; Jeffrey P Krischer Journal: Diabetes Care Date: 2016-06-16 Impact factor: 17.152
Authors: Tihamer Orban; Jay M Sosenko; David Cuthbertson; Jeffrey P Krischer; Jay S Skyler; Richard Jackson; Liping Yu; Jerry P Palmer; Desmond Schatz; George Eisenbarth Journal: Diabetes Care Date: 2009-09-09 Impact factor: 17.152
Authors: Petra M Pöllänen; Samppa J Ryhänen; Jorma Toppari; Jorma Ilonen; Paula Vähäsalo; Riitta Veijola; Heli Siljander; Mikael Knip Journal: J Clin Endocrinol Metab Date: 2020-12-01 Impact factor: 5.958